Brain neuropeptide Y (NPY) in stress and alcohol dependence

Reviews in the Neurosciences

Volumn 13, Issue 1, 2002, Pages 85-94

  Heilig, Markus ^a   Thorsell, Annika ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alcoholism; Amygdala; Anxiety; Neuropeptide Y; Stress

Indexed keywords

NEUROPEPTIDE Y;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY NEUROSIS; BEHAVIOR; DEPRESSION; EMOTION; GENETIC RECOMBINATION; HORMONE ACTION; HORMONE RESPONSE; HUMAN; KNOCKOUT GENE; MICROINJECTION; MOUSE; NEUROENDOCRINOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; REVIEW; STRESS; TRANSGENIC ANIMAL;

ALCOHOLISM; ANIMALS; ANXIETY; ARGININE; BEHAVIOR, ANIMAL; BENZAZEPINES; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMANS; NEUROPEPTIDE Y; RECEPTORS, NEUROPEPTIDE Y; STRESS;

EID: 0036379253     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Allen JM, Balbi D. Structure and expression of the neuropeptide Y gene. In: Colmers WF, Wahlestedt C, eds. The Biology of Neuropeptide Y and Related Peptides. Totowa, NJ: Humana Press, 1993; 43-64.
2. Andrews N, File SE, Fernandes C, Gonzalez LE, Barnes NM. Evidence that the median raphe nucleusdorsal hippocampal pathway mediates diazepam withdrawal-induced anxiety. Psychopharmacology 1997; 130: 228-234.
3. Badia-Elder NE, Stewart RB, Powrozek TA, Roy KF, Murphy JM, Li TK. Effect of neuropeptide Y (NPY) on oral ethanol intake in Wistar, alcohol-preferring (P), and -nonpreferring (NP) rats. Alcohol Clin Exp Res 2001; 25: 386-390.
4. Bai FL, Yamano M, Shiotani Y, Emson PC, Smith AD, Powell JF, Tohyama M. An arcuato-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat. Brain Res 1985; 331: 172-175.
5. Bard JA, Walker MW, Branchek TA, Weinshank RL. Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem 1995; 270: 26762-26765.
6. Bellman R, Sperk G. Effects of antidepressant drug treatment on levels of NPY or prepro-NPY-mRNA in the rat brain. Neurochem Int 1993; 22: 183-187.
7. Berrettini WH, Doran AR, Kelsoe J, Roy A, Pickar D. Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. Neuropsychopharmacology 1987; 1: 81-83.
8. Bice P, Foroud T, Bo RH, Castelluccio P, Lumeng L, Li TK, Carr LG. Genomic screen for QTLs underlying alcohol consumption in the P and NP rat lines. Mamm Genome 1998; 9: 949-955.
9. Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL. Behavioral effects of neuropeptide receptor agonists in the elevated plus-maze and fear-potentiated startle procedure. Behav Pharmacol 1995; 6: 215-222.
10. Caberlotto L, Fuxe K, Overstreet DH, Gerrard P, Hurd YL. Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Brain Res Mol Brain Res 1998; 59: 58-65.
11. Caberlotto L, Hurd YL. Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. NeuroReport 1999; 10: 1747-1750.
12. Caberlotto L, Jimenez P, Overstreet DH, Hurd YL, Mathe AA, Fuxe K. Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression. Neurosci Lett 1999; 265: 191-194.
13. Caberlotto L, Thorsell A, Rimondini R, Sommer W, Hyytia P, Heilig M. Differential expression of NPY and its receptors in alcohol preferring AA and alcohol avoiding ANA rats. Alcohol Clin Exp Res 2001; 25: 1564-1569.
14. Carr LG, Foroud T, Bice P, Gobbett T, Ivashina J, Edenberg H, Lumeng L, Li TK. A quantitative trait locus for alcohol consumption in selectively bred rat lines. Alcohol Clin Exp Res 1998; 22: 884-887.
15. Chojnacka-Wojcik E, Tatarczynska E, Pilc A. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. Eur J Pharmacol 1997; 319: 153-156.
16. Davis M. Neurobiology of fear responses: the role of the amygdala. J Neuropsychiatr Clin Neurosci 1997; 9: 382-402.
17. De Quidt ME, Emson PC. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system - I. Radioimmunoassay and chromatographic characterisation. Neuroscience 1986; 18: 527-543.
18. De Quidt ME, Emson PC. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system - II. Immunohistochemical analysis. Neuroscience 1986; 18: 545-618.
19. Ehlers CL, Li TK, Lumeng L, Hwang BH, Somes C, Jimenez P, Mathe AA. Neuropeptide Y levels in ethanol-naive, alcohol-preferring, and nonpreferring rats and in Wistar rats after ethanol exposure. Alcohol Clin Exp Res 1998; 22: 1778-1782.
20. Ehlers CL, Somes C, Cloutier D. Are some of the effects of ethanol mediated through NPY? Psychopharmacology 1998; 139: 136-144.
21. Eva C, Keinanen K, Monyer H, Seeburg P, Sprengel R. Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family. FEBS Lett 1990; 271: 81-84.
22. File SE. The interplay of learning and anxiety in the elevated plus-maze. Behav Brain Res 1993; 58: 199-202.
23. Fuxe K, Agnati LF, Härfstrand A, Zini I, Tatemoto K, Pich EM, Hökfelt T, Mutt V, Terenius L. Central administration of neuropeptide Y induces hypotension bradypnea and EEG synchronization in the rat. Acta Physiol Scand 1983; 118: 189-192.
24. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzlhartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA, Weinshank RL. A receptor subtype involved in neuropeptide-Y- induced food intake. Nature 1996; 382: 168-171.
25. Gerald C, Walker MW, Vaysse PJ, He C, Branchek TA, Weinshank RL. Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J Biol Chem 1995; 270: 26758-26761.
26. Glaum SR, Miller RJ, Rhim H, Maclean D, Georgic LM, MacKenzie RG, Grundemar L. Characterization of Y3 receptor-mediated synaptic inhibition by chimeric neuropeptide Y-peptide YY peptides in the rat brainstem. Br J Pharmacol 1997; 120: 481-487.
27. Gonzalez LE, File SE, Overstreet DH. Selectively bred lines of rats differ in social interaction and hippocampal 5-HTIA receptor function: a link between anxiety and depression? Pharmacol Biochem Behav 1998; 59: 787-792.
28. Heilig M. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic like action of NPY in amygdala and paradoxically increases feeding. Regul Peptides 1995; 59: 201-205.
29. Heilig M, Ekman R. Chronic parenteral antidepressant treatment in rats: unaltered levels and processing of neuropeptide Y (NPY) and corticotropin-releasing hormone (CRH). Neurochem Int 1995; 26: 351-355.
30. Heilig M, Koob GF, Ekman R, Britton KT. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci 1994; 17: 80-85.
31. Heilig M, McLeod S, Brot M, Heinrichs SC, Menzaghi F, Koob GF, Britton KT. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 1993; 8: 357-363.
32. Heilig M, McLeod S, Koob GF, Britton KT. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Peptides 1992; 41: 61-69.
33. Heilig M, Murison R. Intracerebroventricular neuropeptide Y protects against stress-induced gastric erosion in the rat. Eur J Pharmacol 1987; 137: 127-129.
34. Heilig M, Murison R. Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat. Regul Peptides 1987; 19: 221-231.
35. Heilig M, Söderpalm B, Engel JA, Widerlöv E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology 1989; 98: 524-529.
36. Heilig M, Vecsei L, Widerlöv E. Opposite effects of centrally administered neuropeptide Y (NPY) on locomotor activity of spontaneously hypertensive (SH) and normal rats. Acta Physiol Scand 1989; 137: 243-248.
37. Heilig M, Wahlestedt C, Ekman R, Widerlöv E. Anti- depressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. Eur J Pharmacol 1988; 147: 465-467.
38. Hendry SH. Organization of neuropeptide Y neurons in the mammalian central nervous system. In: Wahlestedt C, Colmers WF, eds. The Biology of Neuropeptide Y and Related Peptides. Totowa, NJ: Humana Press, 1993; 65-156.
39. Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci USA 1992; 89: 5794-5798.
40. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 1996; 54: 21-30.
41. Husum H, Mikkelsen JD, Hogg S, Mathe AA, Mork A. Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 2000; 39: 1463-1473.
42. Hwang BH, Zhang JK, Ehlers CL, Lumeng L, Li TK. Innate differences of neuropeptide Y (NPY) in hypothalamic nuclei and central nucleus of the amygdala between selectively bred rats with high and low alcohol preference. Alcohol Clin Exp Res 1999; 23: 1023-1030.
43. Jazin EE, Yoo H, Blomqvist AG, Yee F, Weng G, Walker MW, Salon J, Larhammar D, Wahlestedt C. A proposed bovine neuropeptide Y (NPY) receptor cDNA clone, or its human homologue, confers neither NPY binding sites nor NPY responsiveness on transfected cells. Regul Peptides 1993; 47: 247-258.
44. Jimenez P, Salmi P, Ahlenius S, Mathe AA. Neuropeptide Y in brains of the Flinders Sensitive Line rat, a model of depression. Effects of electroconvulsive stimuli and d-amphetamine on peptide concentrations and locomotion. Behav Brain Res 2000; 111: 115-123.
45. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, Dekker JM, Hart LM, Valve R, Uusitupa MIJ. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nature Med 1998; 4: 1434-1437.
46. Kask A, Rago L, Harro J. Anxiogenic-like effect of the neuropeptide Y Y-1 receptor antagonist BIBP3226 -antagonism with diazepam. Eur J Pharmacol 1996; 317: R3-R4.
47. Kask A, Rago L, Harro J. Anxiogenic-like effect of the NPY Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats. Regul Peptides 1998; 75-76: 255-262.
48. Kauhanen J, Karvonen MK, Pesonen U, Koulu M, Tuomainen TP, Uusitupa MI, Salonen JT. Neuropeptide Y polymorphism and alcohol consumption in middle-aged men. Am J Med Genet 2000; 93: 117-121.
49. King PJ, Widdowson PS, Doods HN, Williams G. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J Neurochem 1999; 73: 641-646.
50. King PJ, Williams G, Doods H, Widdowson PS. Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release. Eur J Pharmacol 2000; 396: R1-R3.
51. Larhammar D, Blomqvist AG, Yee F, Jazin E, Yoo H, Wahlestedt C. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem 1992; 267: 10935-10938.
52. Larhammar D, Ericsson A, Persson H. Structure and expression of the rat neuropeptide Y gene. Proc Natl Acad Sci USA 1987; 84: 2068-2072.
53. Larhammar D, Söderberg C, Blomqvist AG. Evolution of the neuropeptide Y family of peptides. In: Colmers WF, Wahlestedt C, eds. The Biology of Neuropeptide Y and Related Peptides. Totowa, NJ: Humana Press, 1993; 1-41.
54. Lundberg JM, Torssell L, Sollevi A, Pemow J, Theodorsson N, Änggård A, Hamberger B. Neuropeptide Y and sympathetic vascular control in man. Regul Peptides 1985; 13: 41-52X.
55. Lundell I, Blomqvist AG, Berglund MM, Schober DA, Johnson D, Statnick MA, Gadski RA, Gehlert DR, Larhammar D. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J Biol Chem 1995; 270: 29123-29128.
56. McCreary AC, McBlane JW, Spooner HA, Handley SL. 5-HT systems and anxiety: multiple mechanisms in the elevated X-maze. Polish J Pharmacol 1996; 48: 1-12.
57. McQuiston AR, Colmers WF. Neuropeptide Y2 receptors inhibit the frequency of spontaneous but not miniature EPSCs in CA3 pyramidal cells of rat hippocampus. J Neurophysiol 1996; 76: 3159-3168.
58. Minth CD, Bloom SR, Polak JM, Dixon JE. Cloning, characterization, and DNA sequence of a human cDNA encoding neuropeptide tyrosine. Proc Natl Acad Sci USA 1984; 81: 4577-4581.
59. Naveilhan P, Canals JM, Valjakka A, Vartiainen J, Arenas E, Ernfors P. Neuropeptide Y alters sedation through a hypothalamic Y1-mediated mechanism. Eur J Neurosci 2001; 13: 2241-2246.
60. 2+ entry. J Neurosci 1997; 17: 8169-8177.
61. Redrobe JP, Fournier A, Quirion R. Antidepressant-like activity of neuropeptide Y (NPY) in the mouse forced swim test: role of NPY Y1 and NPY Y2 receptor subtypes. Summer Neuropeptide Conference, 2000; Abst.
62. Rodgers RJ. Animal models of 'anxiety': Where next? Behav Pharmacol 1997; 8: 477-496.
63. Sabol SL, Higuchi H. Transcriptional regulation of the neuropeptide Y gene by nerve growth factor: antagonism by glucocorticoids and potentiation by adenosine 3′,5′-monophosphate and phorbol ester. Mol Endocrinol 1990; 4: 384-392.
64. Sajdyk TJ, Vandergriff MG, Gehlert DR. Amygdalar neuropeptide Y Y-1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 1999; 368: 143-147.
65. Schwartz TW, Fuhlendorff J, Kjems LL, Kristensen MS, Vervelde M, O'Hare M, Krstenansky JL, Bjornholm B. Signal epitopes in the three-dimensional structure of neuropeptide Y. Interaction with Y1, Y2, and pancreatic polypeptide receptors. Ann NY Acad Sci 1990; 611: 35-47.
66. 2 receptors for neuropeptide Y. FEBS Lett 1989; 245: 209-214.
67. Slawecki CJ, Betancourt M, Walpole T, Ehlers CL. Increases in sucrose consumption, but not ethanol consumption, following 1CV NPY administration. Pharmacol Biochem Behav 2000; 66: 591-594.
68. Stenfors C, Theodorsson E, Mathe AA. Effect of repeated electroconvulsive treatment on regional concentrations of tachykinins, neurotensin, vasoactive intestinal polypeptide, neuropeptide Y, and galanin in rat brain. J Neurosci Res 1989; 24: 445-450.
69. Tatemoto K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci USA 1982; 79: 2514-2518.
70. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci USA 1982; 79: 5485-5489.
71. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982; 296: 659-660.
72. Thiele TE, Koh MT, Pedrazzini T. Voluntary ethanol consumption is controlled via the neuropeptide Y Y1 receptor. J Neurosci 2002; 22: RC208.
73. Thiele TE, Marsh DJ, Ste M, Bernstein IL, Palmiter RD. Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 1998; 396: 366-369.
74. Thorsell A, Carlsson K, Ekman R, Heilig M. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. NeuroReport 1999; 10: 3003-3007.
75. Thorsell A, Michalkiewicz M, Dumont Y, Quirion R, Caberlotto L, Rimondini R, Mathe AA, Heilig M. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci USA 2000; 97: 12852-12857.
76. Thorsell A, Rimondini R, Heilig M. Blockade of central neuropeptide Y (NPY) Y2 receptor reduces ethanol self-administration in rats. Neurosci Lett, in press
77. Thorsell A, Svensson P, Wiklund L, Sommer W, Ekman R, Heilig M. Suppressed neuropeptide Y (NPY) mRNA in rat amygdala following restraint stress. Regul Peptides 1998; 75-6: 247-254.
78. Wahlestedt C, Blendy JA, Kellar KJ, Heilig M, Widerlöv E, Ekman R. Electroconvulsive shocks increase the concentration of neocortical and hippocampal neuropeptide Y (NPY)-like immunoreactivity in the rat. Brain Res 1990; 507: 65-68.
79. Wahlestedt C, Karoum F, Jaskiw G, Wyatt RJ, Larhammar D, Ekman R, Reis DJ. Cocaine-induced reduction of brain neuropeptide Y synthesis dependent on medial prefrontal cortex. Proc Natl Acad Sci USA 1991; 88: 2078-2082.
80. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 1993; 259: 528-531.
81. Wahlestedt C, Yanaihara N, Hakanson R. Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides. Regul Peptides 1986; 13: 307-318.
82. Widdowson PS, Ordway GA, Halaris AE. Reduced neuropeptide Y concentrations in suicide brain. J Neurochem 1992; 59: 73-80.
83. Widerlöv E, Lindström LH, Wahlestedt C, Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiat Res 1988; 22: 69-79.
84. Woldbye DP, Larsen PJ, Mikkelsen JD, Klemp K, Madsen TM, Bolwig TG. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nature Med 1997; 3: 761-764.
85. Woldbye DP, Madsen TM, Larsen PJ, Mikkelsen JD, Bolwig TG. Neuropeptide Y inhibits hippocampal seizures and wet dog shakes. Brain Res 1996; 737: 162-168.
86. Wraith A, Tornsten A, Chardon P, Harbitz I, Chowdhary BP, Andersson L, Lundin LG, Larhammar D. Evolution of the neuropeptide Y receptor family: gene and chromosome duplications deduced from the cloning and mapping of the five receptor subtype genes in pig. Genome Res 2000; 10: 302-310.